Cancer

Establishment Labs Announces Commercial Launch of Motiva Implants in China

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

5 months ago

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands Erasmus Medical Center Erasmus Medical Center OCALA, Fla., Jan.…

5 months ago

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024…

5 months ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New…

5 months ago

SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.

HUMMELSTOWN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based…

5 months ago

Angle PLC Announces Potential Utility in Precision Oncology

REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGYPaper published in the journal "Current…

5 months ago

Defence Financing

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…

5 months ago

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual…

5 months ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees…

5 months ago

Imugene’s CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium

SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to…

5 months ago